Literature DB >> 26979523

The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?

Benedikt A Aulinger1, Torsten P Vahl2, Ron L Prigeon3, David A D'Alessio4, Deborah A Elder5.   

Abstract

The incretin effect reflects the actions of enteral stimuli to promote prandial insulin secretion. Impairment of this measure has been proposed as an early marker of β-cell dysfunction and described in T2D, IGT, and even obesity without IGT. We sought to determine the effects of obesity and diabetes on the incretin effect in young subjects with short exposures to metabolic abnormalities and a few other confounding medical conditions. Subjects with T2D (n = 10; 18.0 ± 0.4 yr) or NGT, either obese (n = 11; 17.7 ± 0.4 yr) or lean (n = 8; 26.5 ± 2.3 yr), had OGTT and iso-iv. The incretin effect was calculated as the difference in insulin secretion during these tests and was decreased ∼50% in both the NGT-Ob and T2D subjects relative to the NGT-Ln group. The T2D group had impaired glucose tolerance and insulin secretion during the OGTT, whereas the lean and obese NGT subjects had comparable glucose excursions and β-cell function. During the iso-iv test, the NGT-Ob subjects had significantly greater insulin secretion than the NGT-Ln and T2D groups. These findings demonstrate that in young subjects with early, well-controlled T2D the incretin effect is reduced, similar to what has been described in diabetic adults. The lower incretin effect calculated for the obese subjects with NGT is driven by a disproportionately greater insulin response to iv glucose and does not affect postprandial glucose regulation. These findings confirm that the incretin effect is an early marker of impaired insulin secretion in persons with abnormal glucose tolerance but suggest that in obese subjects with NGT the incretin effect calculation can be confounded by exaggerated insulin secretion to iv glucose.

Entities:  

Keywords:  glucagon-like peptide-1; glucose tolerance; glucose-dependent insulinotropic polypeptide; incretin effect; insulin secretion

Mesh:

Substances:

Year:  2016        PMID: 26979523      PMCID: PMC4867309          DOI: 10.1152/ajpendo.00496.2015

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  42 in total

Review 1.  Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

Authors:  S E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

Review 2.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

3.  Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.

Authors:  Torsten P Vahl; Breay W Paty; Bradley D Fuller; Ronald L Prigeon; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

4.  Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice.

Authors:  K Miyawaki; Y Yamada; H Yano; H Niwa; N Ban; Y Ihara; A Kubota; S Fujimoto; M Kajikawa; A Kuroe; K Tsuda; H Hashimoto; T Yamashita; T Jomori; F Tashiro; J Miyazaki; Y Seino
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

5.  Plasma insulin and glucose responses of healthy subjects to varying glucose loads during three-hour oral glucose tolerance tests.

Authors:  A Castro; J P Scott; D P Grettie; D Macfarlane; R E Bailey
Journal:  Diabetes       Date:  1970-11       Impact factor: 9.461

Review 6.  New developments in the incretin concept.

Authors:  W Creutzfeldt; R Ebert
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

7.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

Authors:  W K Ward; D C Bolgiano; B McKnight; J B Halter; D Porte
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

8.  The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

Authors:  Lise L Kjems; Jens J Holst; Aage Vølund; Sten Madsbad
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

9.  Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects.

Authors:  M J Perley; D M Kipnis
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

Review 10.  Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.

Authors:  Jens J Holst; Filip K Knop; Tina Vilsbøll; Thure Krarup; Sten Madsbad
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

View more
  6 in total

1.  Effects of small intestinal glucose on glycaemia, insulinaemia and incretin hormone release are load-dependent in obese subjects.

Authors:  L G Trahair; C S Marathe; S Standfield; C K Rayner; C Feinle-Bisset; M Horowitz; K L Jones
Journal:  Int J Obes (Lond)       Date:  2016-12-06       Impact factor: 5.095

Review 2.  Methods for Measuring Risk for Type 2 Diabetes in Youth: the Oral Glucose Tolerance Test (OGTT).

Authors:  Melinda E Chen; Rebecca S Aguirre; Tamara S Hannon
Journal:  Curr Diab Rep       Date:  2018-06-16       Impact factor: 4.810

3.  Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats.

Authors:  Benedikt A Aulinger; Marta Perabo; Randy J Seeley; Klaus G Parhofer; David A D'Alessio
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-11-19       Impact factor: 4.310

4.  A Reduced Incretin Effect Mediated by the rs7903146 Variant in the TCF7L2 Gene Is an Early Marker of β-Cell Dysfunction in Obese Youth.

Authors:  Alfonso Galderisi; Domenico Tricò; Bridget Pierpont; Veronika Shabanova; Stephanie Samuels; Chiara Dalla Man; Brittany Galuppo; Nicola Santoro; Sonia Caprio
Journal:  Diabetes Care       Date:  2020-08-11       Impact factor: 19.112

5.  Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus.

Authors:  Toh Peng Yeow; Giovanni Pacini; Andrea Tura; Chee Peng Hor; Shueh Lin Lim; Florence Hui Sieng Tan; Chin Voon Tong; Janet Yeow Hua Hong; Fuziah Md Zain; Jens Juul Holst; Wan Nazaimoon Wan Mohamud
Journal:  BMJ Open Diabetes Res Care       Date:  2017-03-10

Review 6.  Enteroendocrine System and Gut Barrier in Metabolic Disorders.

Authors:  Céline Osinski; Dounia Moret; Karine Clément; Patricia Serradas; Agnès Ribeiro
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.